Management of psoriatic arthritis

Indian Journal of Dermatology, Venereology and Leprology

Volumn 76, Issue 6, 2010, Pages 645-651

  Sharma, Aman ^a   Dogra, Sunil ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

management; Psoriasis; psoriatic arthritis

Indexed keywords

ADALIMUMAB; ALEFACEPT; AURANOFIN; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; ETRETINATE; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; USTEKINUMAB;

ANOREXIA; AZOOSPERMIA; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG USE; DYSPEPSIA; EARLY DIAGNOSIS; FATIGUE; GINGIVA HYPERTROPHY; HEADACHE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INFECTION; INFUSION REACTION; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; MOUTH ULCER; NAUSEA; NEPHROTOXICITY; PATIENT MONITORING; PSORIATIC ARTHRITIS; SIDE EFFECT; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; STOMATITIS; TERATOGENICITY; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; DISEASE MANAGEMENT; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649273739     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.72457     Document Type: Conference Paper

References (55)

1. Alibert JL. Precis Theoretique sur les maladies de la peau. Paris: Caille et Ravier; 1818. p. 21.
2. Blumberg BS, Bunim JJ, Calkins E, Pirani CL, Zvaifler NJ. Nomenclature and classification of arthritis and rheumatism (tentative) accepted by the American Rheumatism Association. Bull Rheum Dis 1964;14:339-40.
3. Gladmann DD. Psoriatic arthritis. In: Gordon K, Ruderman E, editors. Psoriasis and psoriatic arthritis. Berlin: Springer-Verlag; 2005. p. 57-65.
4. Bedi TR. Clinical profile of psoriasis in North India. Indian J Dermatol Venereol Leprol 1995;61:202-5.
5. Moll JM, Wright V. Familial occurrence of PsA. Ann Rheum Dis 1973;32:181-201.
6. Malviya AN, Dasgupta B, Tiwari SC, Khan KM, Pasricha JS, Mehra NK. Psoriatic arthritis: A clinical and immunological study in 15 cases from India. J Assoc Physicians India 1984;32:403-5.
7. Rajendran C P, Ledge SG, Rani K P, Madhavan R. Psoriatic arthritis. J Assoc Physicians India 2003;51:1065-8.
8. th ed. Philadelphia: Lea and Febiger; 1979. p. 645.
9. Vasey F, Espinoza LR. Psoriatic arthritis. In: Calin A, editors. Spondyloarthropathies. Orlando, Fla: Grune and Stratton; 1984. p. 151-85.
10. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis-an analysis of 220 patients. Q J Med 1987;238:127-41.
11. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis. A unified concept twenty years on. Arthritis Rheum 1999;42:1080-6.
12. Fournie B, Crognier L, Arnaud C, Zabraniecki L, Lascaux-Lefebvre V, Marc V, et al. Proposed classification criteria of Psoriatic arthritis. A preliminary study in 260 patients. Rev Rhum Eng Ed 1999;66:446-56.
13. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
14. Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001;28:1021-44.
15. Girolomini G, Gisondi P. Psoriasis and systemic inflammation; underdiagnosed enthesopathy. J Eur Acad Dermatol Venerol 2009;23:3-8.
16. Husted JA, Gladmann DD, Farewell VT, Cook RJ. Health related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis care Res 2001;45:151-8.
17. Mease PJ. Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol 2004;16:366-70.
18. Bakker M F, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: Efficacy and feasibility. Ann Rheum Dis 2007;66:56-60.
19. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64:14-7.
20. Qureshi AA, Dominguez P, Duffin KC, Gladman DD, Helliwell P, Mease PJ, et al. Psoriatic arthritis screening tools. J Rheumatol 2008;35:1423-5.
21. Griffith CEM. Therapy for psoriatic arthritis: Sometimes a conflict for psoriasis. Br J Rheumatol 1997;36:409-12.
22. st ed. Philadelphia: Publishers Mosby; p. 97-113. 2007
23. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. New Eng J Med 1995;333:142-6.
24. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-39.
25. Black RL, O'Brien WM, Van Scott EJ, Auerbach R, Eisen AZ, BunimJJ. Methotrexate therapy in psoriatic arthritis. JAMA 1964;189:141.
26. Kragballe K, Zachariae E, Zachariae H. Methotrexate in psoriatic arthritis: A retrospective study. Acta Derm Venereol 1983;63:165-7.
27. Espinoza LR, Zakraoui L, Espinoza CG, Gutiérrez F, Jara LJ, Silveira LH, et al. Psoriatic arthritis: Clinical response and side effects to methotrexate therapy. J Rheumatol 1992;19:872-7.
28. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis http://www.cochrane.org/reviews/en/ab000212.html.
29. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
30. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation consensus conference. J Am Acad Dermatol 2009;60:824-37.
31. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009;48:569-72.
32. Singh YN, Verma KK, Kumar A, Malaviya AN. Methotrexate in psoriatic arthritis. J Assoc Physicians India 1994;42:860-2.
33. Chandran V, Gottlieb A, Cook RJ, Duffin KC, Garg A, Helliwell P, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 2009;61:1235-42.
34. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporin: Nested cohort crossover study. Lancet 2001;358:1042-5.
35. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005;64:74-7.
36. Alivernini S, Mazzotta D, Zoli A, Ferraccioli G. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: Retrospective analysis of safety and adherence to treatment. Drugs Aging 2009;26:395-402.
37. Leflunomide: A review of its use in active rheumatoid arthritis. Drugs 1999;58:1137-64.
38. Perlman SG, Gerber LH, Roberts RM, Nigra T P, Barth W F. Photochemotherapy and psoriatic arthritis. A prospective study. Ann Intern Med 1979;91:717-22.
39. Schrader P, Mooser G, Peter RU, Puhl W. Preliminary results in therapy of psoriatic arthritis with mycophenolate mofetil [in German]. Z Rheumatol 2002;61:545-50.
40. Lee JCT, Gladman DD, Schentag CT, Cook RJ. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol 2001;7:160-5.
41. Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992;19:1724-6.
42. Carrette S, Calin A. Evaluation of auranofin in psoriatic arthritis: A double blind placebo controlled trial. Arthritis Rheum 1989;32:158-65.
43. Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990;29:280-3.
44. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
45. Sterry W, Ortonne J P, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Results of a radomized, double-blind study to evaluate the efficacy and safety of etanercept in patients with psoriasis and psoriatic arthritis: the PRESTA trial. Psoriasis Gene to Clinic, London; 2008.
46. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
47. van der Heijde D, Kavanaugh A, Beutler A, Antoni C, Krueger GG, Guzzo C, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56:2698-707. (Pubitemid 47237288)
48. Kraan MC, van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, de Rie MA, et al. Alefacept treatment in psoriatic arthritis: Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002;46:2776-84.
49. Mease PJ, Reich KD. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo controlled study. J Am Acad Dermatol 2008;60:402-11.
50. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double blind, placebo controlled, crossover trial. Lancet 2009;373:633-40.
51. Jung N, Hellmann M, Hoheisel R, Lehmann C, Haase I, Perniok A et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol. 2010 Jun. 9. [Epub ahead of print]
52. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
53. Misra R, Sharma BL, Gupta R, Pandya S, Agarwal S, Agarwal P, et al. Indian Rheumatology Association consensus statement on the management of adults with rheumatoid arthritis. Indian J Rheumatol 2008;39: S1-S6.
54. Misra R, Amin S, Joshi VR, Rao URK, Aggarwal A, Fatima F, et al. Open label evaluation of the efficacy and safety of etanercept in rheumatoid arthritis. J Indian Rheumatol Assoc 2005;13:131-4.
55. Grover R, Kapoor S, Marwaha V, Malaviya AN, Gupta R, Kumar A. Clinical experience with infliximab in spondyloarthropathy: an open label study of 14 patients. J Indian Rheumatol Assoc 2005;13:78-82.